Amalgamated Bank’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $509K | Sell |
28,328
-5,609
| -17% | -$106K | ﹤0.01% | 1360 |
|
|
2026
Q1 | $738K | Sell |
33,937
-1,236
| -4% | -$23.9K | 0.01% | 1192 |
|
|
2025
Q4 | $757K | Buy |
35,173
+3,213
| +10% | +$67.7K | 0.01% | 1171 |
|
|
2025
Q3 | $616K | Sell |
31,960
-14,435
| -31% | -$257K | ﹤0.01% | 1239 |
|
|
2025
Q2 | $793K | Buy |
46,395
+1,436
| +3% | +$61.3K | 0.01% | 1131 |
|
|
2025
Q1 | $2.87M | Sell |
44,959
-1,736
| -4% | -$183K | 0.02% | 613 |
|
|
2024
Q4 | $5.68M | Buy |
46,695
+222
| +0.5% | +$27.2K | 0.05% | 344 |
|
|
2024
Q3 | $5.8M | Sell |
46,473
-2,248
| -5% | -$311K | 0.05% | 341 |
|
|
2024
Q2 | $7.7M | Buy |
48,721
+42,813
| +725% | +$5.5M | 0.07% | 243 |
|
|
2024
Q1 | $765K | Sell |
5,908
-12,260
| -67% | -$1.5M | 0.01% | 1151 |
|
|
2023
Q4 | $1.75M | Sell |
18,168
-2,314
| -11% | -$222K | 0.01% | 963 |
|
|
2023
Q3 | $2.48M | Buy |
20,482
+1,243
| +6% | +$140K | 0.02% | 787 |
|
|
2023
Q2 | $2.2M | Buy |
19,239
+1,540
| +9% | +$199K | 0.02% | 840 |
|
|
2023
Q1 | $2.44M | Sell |
17,699
-1,777
| -9% | -$231K | 0.02% | 795 |
|
|
2022
Q4 | $2.52M | Buy |
19,476
+241
| +1% | +$27.9K | 0.02% | 805 |
|
|
2022
Q3 | $2.13M | Buy |
19,235
+312
| +2% | +$31.4K | 0.02% | 816 |
|
|
2022
Q2 | $1.42M | Sell |
18,923
-252
| -1% | -$18.5K | 0.01% | 1000 |
|
|
2022
Q1 | $1.5M | Buy |
19,175
+1,793
| +10% | +$137K | 0.01% | 1042 |
|
|
2021
Q4 | $1.56M | Buy |
17,382
+3,564
| +26% | +$305K | 0.01% | 1051 |
|
|
2021
Q3 | $1.28M | Sell |
13,818
-841
| -6% | -$64.8K | 0.01% | 1131 |
|
|
2021
Q2 | $1.14M | Buy |
14,659
+650
| +5% | +$49.3K | 0.01% | 1227 |
|
|
2021
Q1 | $1.04M | Sell |
14,009
-1,223
| -8% | -$113K | 0.04% | 533 |
|
|
2020
Q4 | $2.6M | Buy |
15,232
+182
| +1% | +$27K | 0.1% | 165 |
|
|
2020
Q3 | $2.11M | Sell |
15,050
-387
| -3% | -$58.8K | 0.09% | 179 |
|
|
2020
Q2 | $2.48M | Sell |
15,437
-3,171
| -17% | -$432K | 0.11% | 144 |
|
|
2020
Q1 | $1.82M | Sell |
18,608
-538
| -3% | -$61.5K | 0.04% | 395 |
|
|
2019
Q4 | $2.47M | Buy |
19,146
+1,485
| +8% | +$150K | 0.05% | 395 |
|
|
2019
Q3 | $1.33M | Buy |
17,661
+2,063
| +13% | +$244K | 0.03% | 630 |
|
|
2019
Q2 | $2.37M | Buy |
15,598
+440
| +3% | +$53.5K | 0.06% | 331 |
|
|
2019
Q1 | $1.81M | Buy |
15,158
+284
| +2% | +$36.5K | 0.04% | 439 |
|
|
2018
Q4 | $1.62M | Buy |
14,874
+6,300
| +73% | +$788K | 0.05% | 407 |
|
|
2018
Q3 | $1.39M | Sell |
8,574
-5,892
| -41% | -$805K | 0.03% | 518 |
|
|
2018
Q2 | $1.91M | Buy |
14,466
+6,326
| +78% | +$597K | 0.05% | 412 |
|
|
2018
Q1 | $603K | Sell |
8,140
-141
| -2% | -$9.4K | 0.02% | 874 |
|
|
2017
Q4 | $461K | Buy |
8,281
+783
| +10% | +$41.5K | 0.01% | 1029 |
|
|
2017
Q3 | $340K | Buy |
7,498
+873
| +13% | +$34.9K | 0.01% | 1129 |
|
|
2017
Q2 | $223K | Buy |
+6,625
| New | +$216K | 0.01% | 1361 |
|
|
2016
Q4 | – | Sell |
-4,521
| Closed | -$278K | – | 1516 |
|
|
2016
Q3 | $278K | Buy |
+4,521
| New | +$137K | 0.02% | 1063 |
|
Other funds holding SRPT
EAM
CWG
PAM
Amalgamated Bank's SRPT Position: Q2 2026 in Review
Amalgamated Bank reduced its Sarepta Therapeutics (SRPT) stake by 17% in Q2 2026, selling an estimated $106K and leaving 28,328 shares worth $509K. The position accounts for ﹤0.01% of the portfolio, ranked #1360.
Amalgamated Bank first reported a position in SRPT in Q3 2016 and has held it in 38 quarters since. The position peaked at $7.7M in Q2 2024. 134 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Amalgamated Bank held 28,328 shares of Sarepta Therapeutics worth $509K as of Q2 2026.
- Amalgamated Bank sold 5,609 Sarepta Therapeutics shares in Q2 2026, an estimated $106K.
- Sarepta Therapeutics made up ﹤0.01% of Amalgamated Bank's portfolio in Q2 2026, its #1360 holding.
- Amalgamated Bank first reported a position in Sarepta Therapeutics in Q3 2016 and has held it in 38 quarters since.
- Amalgamated Bank's Sarepta Therapeutics position peaked at $7.7M in Q2 2024.
- 134 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Amalgamated Bank's 13F filing for Q2 2026, filed 23 Jul 2026.